Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
603707.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.22B
Close$
Share Statistics
| Market cap | $13.22 Billion |
|---|---|
| Enterprise Value | $13.60 Billion |
| Dividend Yield | $0.10 (1.22%) |
| Earnings per Share | $0.36 |
| Beta | 0.36 |
| Outstanding Shares | 1,614,277,511 |
Return
| Return on Equity | 6.96% |
|---|---|
| Return on Assets | 4.44% |
| Return on Invested Capital | 8.92% |
Valuation & Multiples
| P/E Ratio | 27.37 |
|---|---|
| PEG | -53.54 |
| Price to Sales | 4.09 |
| Price to Book Ratio | 2.05 |
| Enterprise Value to Revenue | 3.45 |
| Enterprise Value to EBIT | 21.3 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$0.15
Average shareholder expectationRevenue Estimate
$998.00 M
Average shareholder expectationNext Earnings Call
Expected Date
October 31, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$998.76 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
1,558 employees
CEO: Yong Qun Tang Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, ...